Slides as losses widen despite progress in pipelines

TLDR

• NRIX stock fell 1.65% as losses widened despite the pipeline’s progress

• Revenues decline sharply as Sanofi’s collaboration contributions decline

• R&D spending is rising due to the rapid expansion of clinical trials

• Bexobrutideg is progressing toward Phase 3 and approval pathway

• Strategic partnerships support long-term pipeline growth

Shares of Nurix Therapeutics (NRIX) fell to $16.08, down 1.65%, reflecting weak sentiment despite continued clinical progress. The stock showed a steady decline during the day with short bounces that failed to hold. The company reported higher losses alongside developing its oncology and immunology pipeline.

Norex Therapeutics, Inc., Inrix

Financial results show rising costs and widening losses

Nurix reported quarterly revenue of $6.3 million, down sharply from $18.5 million a year earlier. This decrease came after contributions from the Sanofi collaboration decreased after the end of the initial research phases. As a result, high pressures affected overall financial performance.

Research and development expenses increased to $84.1 million from $69.7 million in the same period a year earlier. The increase reflects higher clinical activity, staffing costs and manufacturing efforts associated with pipeline expansion. the a company Accelerate enrollment in key trials to support upcoming regulatory milestones.

The net loss widened to $87.2 million compared to $56.4 million in the same quarter last year. Loss per share also rose to $0.79, highlighting higher operating expenses. Despite this, NOREX maintained a strong cash position of $540.7 million to support ongoing programs.

Bexobrutideg is moving into late-stage development

Nurix continues to develop bexobrutideg, its flagship BTK degradation product targeting B-cell malignancies and autoimmune diseases. The Phase 2 study of DAYBreak CLL-201 remains active and is targeting patients with limited treatment options. This trial is intended to support a potential accelerated approval pathway.

the a company It plans to launch a global confirmatory phase III trial by mid-2026. This study will compare bexobrutideg with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia. The program is close to receiving full regulatory approval.

In parallel, Norex is conducting additional studies to expand the potential use cases of the drug. These include early-stage trials and healthy volunteer studies to evaluate safety and drug effects. Therefore, the company continues to build a broad clinical foundation for future indications.

Pipeline expansion and strategic cooperation support growth

Beyond bexobrutideg, Nurix has several candidates in the areas of oncology and immunology. Zileprodomide remains in phase I trials targeting B-cell malignancies, including lymphoma indications. NX-1607 is progressing into early-stage trials for solid tumors and immune-related cancers.

the a company It also strengthens its position through cooperation with key pharmaceutical partners. Sanofi continues to work on the STAT6 analyzer, while Gilead is developing IRAK4 in early human studies. These partnerships provide joint development opportunities and potentially significant payouts.

Nurix reserves the rights to participate in joint development and share in profits from major programs. This structure allows the company to expand participation after clinical validation. As a result, its pipeline strategy combines internal development and external collaboration to drive long-term growth.